Conjunctivitis Treatment Market By Drug Class, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: CONJUNCTIVITIS TREATMENT MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Antibiotics
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Antiviral
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Anti-allergic
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Artificial Tears
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country

CHAPTER 5: CONJUNCTIVITIS TREATMENT MARKET, BY DISEASE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Allergic Conjunctivitis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
5.2.4.1 Seasonal Allergic Conjunctivitis Market size and forecast, by region
5.2.4.2 Perennial Allergic Conjunctivitis Market size and forecast, by region
5.3 Bacterial Conjunctivitis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Viral Conjunctivitis
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: CONJUNCTIVITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Retail Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: CONJUNCTIVITIS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Disease Type
7.2.3.1 North America Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Disease Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Disease Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Disease Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Disease Type
7.3.3.1 Europe Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Disease Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Disease Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Disease Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Disease Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Disease Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Disease Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Disease Type
7.4.3.1 Asia-Pacific Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Disease Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Disease Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Disease Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Disease Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Disease Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Disease Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Disease Type
7.5.3.1 LAMEA Allergic Conjunctivitis Conjunctivitis Treatment Market by Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Disease Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Disease Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Disease Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Disease Type
7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Abbvie Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Ajanta Pharma Limited
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 AFT Pharmaceuticals
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Alembic Pharmaceuticals Ltd
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Bausch Health Companies Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Cipla, Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Grevis Pharmaceutical Private Limited
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Indoco Remedies Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Jabs Biotech Pvt. Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 JAWA Pharmaceuticals Pvt. Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Johnson & Johnson Services Inc
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Novartis AG
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Ocular Therapeutics, Inc
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Santen Pharmaceuticals Co. Ltd.
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Spectra Vision Care Pvt. Ltd
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Teva Pharmaceutical Industries Ltd
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments

List of Tables
Table 1. Global Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 2. Conjunctivitis Treatment Market Size, for Antibiotics, by Region, 2021-2031 ($Million)
Table 3. Conjunctivitis Treatment Market for Antibiotics, by Country, 2021-2031 ($Million)
Table 4. Conjunctivitis Treatment Market Size, for Antiviral, by Region, 2021-2031 ($Million)
Table 5. Conjunctivitis Treatment Market for Antiviral, by Country, 2021-2031 ($Million)
Table 6. Conjunctivitis Treatment Market Size, for Anti-Allergic, by Region, 2021-2031 ($Million)
Table 7. Conjunctivitis Treatment Market for Anti-Allergic, by Country, 2021-2031 ($Million)
Table 8. Conjunctivitis Treatment Market Size, for Artificial Tears, by Region, 2021-2031 ($Million)
Table 9. Conjunctivitis Treatment Market for Artificial Tears, by Country, 2021-2031 ($Million)
Table 10. Global Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 11. Conjunctivitis Treatment Market Size, for Allergic Conjunctivitis, by Region, 2021-2031 ($Million)
Table 12. Conjunctivitis Treatment Market for Allergic Conjunctivitis, by Country, 2021-2031 ($Million)
Table 13. Global Allergic Conjunctivitis Conjunctivitis Treatment Market, by Type, 2021-2031 ($Million)
Table 14. Conjunctivitis Treatment Market, for Seasonal Allergic Conjunctivitis, by Region, 2021-2031 ($Million)
Table 15. Conjunctivitis Treatment Market, for Perennial Allergic Conjunctivitis, by Region, 2021-2031 ($Million)
Table 16. Conjunctivitis Treatment Market Size, for Bacterial Conjunctivitis, by Region, 2021-2031 ($Million)
Table 17. Conjunctivitis Treatment Market for Bacterial Conjunctivitis, by Country, 2021-2031 ($Million)
Table 18. Conjunctivitis Treatment Market Size, for Viral Conjunctivitis, by Region, 2021-2031 ($Million)
Table 19. Conjunctivitis Treatment Market for Viral Conjunctivitis, by Country, 2021-2031 ($Million)
Table 20. Global Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 21. Conjunctivitis Treatment Market Size, for Hospital Pharmacy, by Region, 2021-2031 ($Million)
Table 22. Conjunctivitis Treatment Market for Hospital Pharmacy, by Country, 2021-2031 ($Million)
Table 23. Conjunctivitis Treatment Market Size, for Retail Pharmacy, by Region, 2021-2031 ($Million)
Table 24. Conjunctivitis Treatment Market for Retail Pharmacy, by Country, 2021-2031 ($Million)
Table 25. Conjunctivitis Treatment Market Size, for Online Pharmacy, by Region, 2021-2031 ($Million)
Table 26. Conjunctivitis Treatment Market for Online Pharmacy, by Country, 2021-2031 ($Million)
Table 27. Conjunctivitis Treatment Market, by Region, 2021-2031 ($Million)
Table 28. North America Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 29. North America Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 30. North America Allergic Conjunctivitis Conjunctivitis Treatment Market, by Type, 2021-2031 ($Million)
Table 31. North America Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 32. North America Conjunctivitis Treatment Market, by Country, 2021-2031 ($Million)
Table 33. U.S. Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 34. U.S. Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 35. U.S. Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 36. Canada Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 37. Canada Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 38. Canada Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 39. Mexico Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 40. Mexico Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 41. Mexico Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 42. Europe Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 43. Europe Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 44. Europe Allergic Conjunctivitis Conjunctivitis Treatment Market, by Type, 2021-2031 ($Million)
Table 45. Europe Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 46. Europe Conjunctivitis Treatment Market, by Country, 2021-2031 ($Million)
Table 47. Germany Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 48. Germany Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 49. Germany Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 50. France Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 51. France Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 52. France Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 53. UK Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 54. UK Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 55. UK Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 56. Italy Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 57. Italy Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 58. Italy Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 59. Spain Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 60. Spain Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 61. Spain Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 62. Rest of Europe Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 63. Rest of Europe Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 64. Rest of Europe Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 65. Asia-Pacific Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 66. Asia-Pacific Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 67. Asia-Pacific Allergic Conjunctivitis Conjunctivitis Treatment Market, by Type, 2021-2031 ($Million)
Table 68. Asia-Pacific Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 69. Asia-Pacific Conjunctivitis Treatment Market, by Country, 2021-2031 ($Million)
Table 70. Japan Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 71. Japan Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 72. Japan Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 73. China Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 74. China Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 75. China Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 76. Australia Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 77. Australia Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 78. Australia Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 79. India Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 80. India Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 81. India Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 82. South Korea Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 83. South Korea Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 84. South Korea Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 85. Rest of Asia-Pacific Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 86. Rest of Asia-Pacific Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 87. Rest of Asia-Pacific Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 88. LAMEA Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 89. LAMEA Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 90. LAMEA Allergic Conjunctivitis Conjunctivitis Treatment Market, by Type, 2021-2031 ($Million)
Table 91. LAMEA Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 92. LAMEA Conjunctivitis Treatment Market, by Country, 2021-2031 ($Million)
Table 93. Brazil Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 94. Brazil Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 95. Brazil Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 96. Saudi Arabia Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 97. Saudi Arabia Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 98. Saudi Arabia Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 99. South Africa Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 100. South Africa Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 101. South Africa Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 102. Rest of LAMEA Conjunctivitis Treatment Market, by Drug Class, 2021-2031 ($Million)
Table 103. Rest of LAMEA Conjunctivitis Treatment Market, by Disease Type, 2021-2031 ($Million)
Table 104. Rest of LAMEA Conjunctivitis Treatment Market, by Distribution Channel, 2021-2031 ($Million)
Table 105. Abbvie Inc.: Company Snapshot
Table 106. Abbvie Inc.: Operating Segments
Table 107. Abbvie Inc.: Product Portfolio
Table 108. Abbvie Inc.: Net Sales
Table 109. Abbvie Inc.: Key Strategies
Table 110. Ajanta Pharma Limited: Company Snapshot
Table 111. Ajanta Pharma Limited: Operating Segments
Table 112. Ajanta Pharma Limited: Product Portfolio
Table 113. Ajanta Pharma Limited: Net Sales
Table 114. Ajanta Pharma Limited: Key Strategies
Table 115. Aft Pharmaceuticals: Company Snapshot
Table 116. Aft Pharmaceuticals: Operating Segments
Table 117. Aft Pharmaceuticals: Product Portfolio
Table 118. Aft Pharmaceuticals: Net Sales
Table 119. Aft Pharmaceuticals: Key Strategies
Table 120. Alembic Pharmaceuticals Ltd.: Company Snapshot
Table 121. Alembic Pharmaceuticals Ltd.: Operating Segments
Table 122. Alembic Pharmaceuticals Ltd.: Product Portfolio
Table 123. Alembic Pharmaceuticals Ltd.: Net Sales
Table 124. Alembic Pharmaceuticals Ltd.: Key Strategies
Table 125. Bausch Health Companies Inc.: Company Snapshot
Table 126. Bausch Health Companies Inc.: Operating Segments
Table 127. Bausch Health Companies Inc.: Product Portfolio
Table 128. Bausch Health Companies Inc.: Net Sales
Table 129. Bausch Health Companies Inc.: Key Strategies
Table 130. Cipla, Inc.: Company Snapshot
Table 131. Cipla, Inc.: Operating Segments
Table 132. Cipla, Inc.: Product Portfolio
Table 133. Cipla, Inc.: Net Sales
Table 134. Cipla, Inc.: Key Strategies
Table 135. Grevis Pharmaceutical Private Limited: Company Snapshot
Table 136. Grevis Pharmaceutical Private Limited: Operating Segments
Table 137. Grevis Pharmaceutical Private Limited: Product Portfolio
Table 138. Grevis Pharmaceutical Private Limited: Net Sales
Table 139. Grevis Pharmaceutical Private Limited: Key Strategies
Table 140. Indoco Remedies Ltd.: Company Snapshot
Table 141. Indoco Remedies Ltd.: Operating Segments
Table 142. Indoco Remedies Ltd.: Product Portfolio
Table 143. Indoco Remedies Ltd.: Net Sales
Table 144. Indoco Remedies Ltd.: Key Strategies
Table 145. Jabs Biotech Pvt. Ltd.: Company Snapshot
Table 146. Jabs Biotech Pvt. Ltd.: Operating Segments
Table 147. Jabs Biotech Pvt. Ltd.: Product Portfolio
Table 148. Jabs Biotech Pvt. Ltd.: Net Sales
Table 149. Jabs Biotech Pvt. Ltd.: Key Strategies
Table 150. Jawa Pharmaceuticals Pvt. Ltd.: Company Snapshot
Table 151. Jawa Pharmaceuticals Pvt. Ltd.: Operating Segments
Table 152. Jawa Pharmaceuticals Pvt. Ltd.: Product Portfolio
Table 153. Jawa Pharmaceuticals Pvt. Ltd.: Net Sales
Table 154. Jawa Pharmaceuticals Pvt. Ltd.: Key Strategies
Table 155. Johnson & Johnson Services Inc.: Company Snapshot
Table 156. Johnson & Johnson Services Inc.: Operating Segments
Table 157. Johnson & Johnson Services Inc.: Product Portfolio
Table 158. Johnson & Johnson Services Inc.: Net Sales
Table 159. Johnson & Johnson Services Inc.: Key Strategies
Table 160. Novartis AG: Company Snapshot
Table 161. Novartis AG: Operating Segments
Table 162. Novartis AG: Product Portfolio
Table 163. Novartis AG: Net Sales
Table 164. Novartis AG: Key Strategies
Table 165. Ocular Therapeutics, Inc.: Company Snapshot
Table 166. Ocular Therapeutics, Inc.: Operating Segments
Table 167. Ocular Therapeutics, Inc.: Product Portfolio
Table 168. Ocular Therapeutics, Inc.: Net Sales
Table 169. Ocular Therapeutics, Inc.: Key Strategies
Table 170. Santen Pharmaceuticals Co. Ltd.: Company Snapshot
Table 171. Santen Pharmaceuticals Co. Ltd.: Operating Segments
Table 172. Santen Pharmaceuticals Co. Ltd.: Product Portfolio
Table 173. Santen Pharmaceuticals Co. Ltd.: Net Sales
Table 174. Santen Pharmaceuticals Co. Ltd.: Key Strategies
Table 175. Spectra Vision Care Pvt. Ltd.: Company Snapshot
Table 176. Spectra Vision Care Pvt. Ltd.: Operating Segments
Table 177. Spectra Vision Care Pvt. Ltd.: Product Portfolio
Table 178. Spectra Vision Care Pvt. Ltd.: Net Sales
Table 179. Spectra Vision Care Pvt. Ltd.: Key Strategies
Table 180. Sun Pharmaceuticals Industries Ltd.: Company Snapshot
Table 181. Sun Pharmaceuticals Industries Ltd.: Operating Segments
Table 182. Sun Pharmaceuticals Industries Ltd.: Product Portfolio
Table 183. Sun Pharmaceuticals Industries Ltd.: Net Sales
Table 184. Sun Pharmaceuticals Industries Ltd.: Key Strategies
Table 185. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 186. Teva Pharmaceutical Industries Ltd.: Operating Segments
Table 187. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 188. Teva Pharmaceutical Industries Ltd.: Net Sales
Table 189. Teva Pharmaceutical Industries Ltd.: Key Strategies

List of Figures
Figure 1. Conjunctivitis Treatment Market Segmentation
Figure 2. Conjunctivitis Treatment Market, 2021-2031
Figure 3. Conjunctivitis Treatment Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Conjunctivitis Treatment Mark.:Drivers, Restraints and Opportunities
Figure 12. Conjunctivitis Treatment Market, By Drug Class, 2021(%)
Figure 13. Comparative Share Analysis of Antibiotics Conjunctivitis Treatment Market, 2021-2031(%)
Figure 14. Comparative Share Analysis of Antiviral Conjunctivitis Treatment Market, 2021-2031(%)
Figure 15. Comparative Share Analysis of Anti-Allergic Conjunctivitis Treatment Market, 2021-2031(%)
Figure 16. Comparative Share Analysis of Artificial Tears Conjunctivitis Treatment Market, 2021-2031(%)
Figure 17. Conjunctivitis Treatment Market, By Disease Type, 2021(%)
Figure 18. Comparative Share Analysis of Allergic Conjunctivitis Conjunctivitis Treatment Market, 2021-2031(%)
Figure 19. Comparative Share Analysis of Bacterial Conjunctivitis Conjunctivitis Treatment Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Viral Conjunctivitis Conjunctivitis Treatment Market, 2021-2031(%)
Figure 21. Conjunctivitis Treatment Market, By Distribution Channel, 2021(%)
Figure 22. Comparative Share Analysis of Hospital Pharmacy Conjunctivitis Treatment Market, 2021-2031(%)
Figure 23. Comparative Share Analysis of Retail Pharmacy Conjunctivitis Treatment Market, 2021-2031(%)
Figure 24. Comparative Share Analysis of Online Pharmacy Conjunctivitis Treatment Market, 2021-2031(%)
Figure 25. Conjunctivitis Treatment Market by Region, 2021
Figure 26. U.S. Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 27. Canada Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 28. Mexico Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 29. Germany Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 30. France Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 31. Uk Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 32. Italy Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 33. Spain Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 34. Rest of Europe Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 35. Japan Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 36. China Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 37. Australia Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 38. India Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 39. South Korea Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 40. Rest of Asia-Pacific Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 41. Brazil Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 42. Saudi Arabia Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 43. South Africa Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 44. Rest of LAMEA Conjunctivitis Treatment Market, 2021-2031($Million)
Figure 45. Top Winning Strategies, by Year
Figure 46. Top Winning Strategies, by Development
Figure 47. Top Winning Strategies, by Company
Figure 48. Product Mapping of Top 10 Players
Figure 49. Competitive Dashboard
Figure 50. Competitive Heatmap of Top 10 Key Players
Figure 51. Abbvie In.: Net Sales, ($Million)
Figure 52. Ajanta Pharma Limite.: Net Sales, ($Million)
Figure 53. Aft Pharmaceutical.: Net Sales, ($Million)
Figure 54. Alembic Pharmaceuticals Lt.: Net Sales, ($Million)
Figure 55. Bausch Health Companies In.: Net Sales, ($Million)
Figure 56. Cipla, Inc.: Net Sales, ($Million)
Figure 57. Grevis Pharmaceutical Private Limite.: Net Sales, ($Million)
Figure 58. Indoco Remedies Ltd.: Net Sales, ($Million)
Figure 59. Jabs Biotech Pvt. Ltd.: Net Sales, ($Million)
Figure 60. Jawa Pharmaceuticals Pvt. Lt.: Net Sales, ($Million)
Figure 61. Johnson & Johnson Services In.: Net Sales, ($Million)
Figure 62. Novartis A.: Net Sales, ($Million)
Figure 63. Ocular Therapeutics, In.: Net Sales, ($Million)
Figure 64. Santen Pharmaceuticals Co. Ltd.: Net Sales, ($Million)
Figure 65. Spectra Vision Care Pvt. Lt.: Net Sales, ($Million)
Figure 66. Sun Pharmaceuticals Industries Lt.: Net Sales, ($Million)
Figure 67. Teva Pharmaceutical Industries Lt.: Net Sales, ($Million)

Executive Summary

According to the report, “Conjunctivitis Treatment Market," the conjunctivitis treatment market was valued at $4.2 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 3.8% from 2022 to 2031.

Conjunctivitis refers to the inflammation or infection of the conjunctiva. It is the most common presentation of eye redness in both primary care and the emergency department, therefore putting a large strain on the healthcare system. Conjunctivitis is a common cause of eye redness and subsequently a common complaint in the emergency department, urgent care, and primary care clinics. It can affect people of any age, demographic or socioeconomic status. Although usually self-limiting and rarely resulting in vision loss, when assessing for conjunctivitis, it is essential to rule out other sight-threatening causes of red-eye. The conjunctiva is the transparent, lubricating mucous membrane covering the outer surface of the eye. It is composed of two parts, the “bulbar conjunctiva” which covers the globe and the “tarsal conjunctiva” which lines the eyelid's inner surface. Conjunctivitis refers to the inflammation or infection of the conjunctiva. It can be acute or chronic and infectious or non-infectious. Acute conjunctivitis refers to symptom duration 3 to 4 weeks from presentation (usually only lasting 1 to 2 weeks) whereas chronic is defined as lasting more than 4 weeks.

Increase in access to diagnostic tests for conjunctivitis, rise in R&D activities by the market players, surge in strategic collaborations among the market players, and increase in product launches and approvals are expected to drive the growth of the global Conjunctivitis Treatment Industry. In addition, focus of governments on awareness programs, and rise in healthcare expenditure and pollution propel the gConjunctivitis Treatment Market growth. Further, different technologies employed in the development of effective treatment boost the growth of Conjunctivitis Treatment Market size.

However, high monetary inputs associated with manufacturing of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The conjunctivitis treatment market is segmented on the basis of disease type, drug class, distribution channel, and region. By disease type, it is classified into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. Based on drug class, it is categorized into antibiotics, antiviral, anti-allergic, and artificial tears. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

By disease type, the allergic conjunctivitis segment generated the highest revenue in the conjunctivitis treatment market in 2021 owing to increase in prevalence of allergic conjunctivitis. By drug class, the anti-allergic segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to advancements in anti-allergic drugs and new product launch. By distribution channel, the hospital pharmacy segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to increase in number of hospital pharmacy.

By region, North America accounted for the largest market share in the Conjunctivitis Treatment Market share in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of conjunctivitis, presence of well-established healthcare infrastructure and rise in healthcare expenditure. However, Asia-Pacific witnessed the highest growth rate for the conjunctivitis treatment market and is expected to continue this Conjunctivitis Treatment Market trends throughout the forecast period, which is attributed to presence of high population base and increase in healthcare expenditure.

The report provides a comprehensive analysis of the key players that operate in the global conjunctivitis treatment market. The key companies profiled in the report include AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, , Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd and Teva Pharmaceutical Industries Ltd.

Key Findings of the Study

• On the basis of disease type, the allergic conjunctivitis segment held 4.3% share in the global market in 2021.
• On the basis of drug class, the anti-allergic segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• On the basis of distribution channel, the hospital pharmacy segment held the largest market share in 2021, and is expected to remain dominant throughout the forecast period.
• Region wise, North-America is expected to experience the highest market share during the forecast period.

Companies Mentioned

• Abbvie Inc
• Ajanta Pharma Limited
• AFT Pharmaceuticals
• Alembic Pharmaceuticals Ltd
• Bausch Health Companies Inc
• Cipla, Inc.
• Grevis Pharmaceutical Private Limited
• Indoco Remedies Ltd.
• Jabs Biotech Pvt. Ltd.
• JAWA Pharmaceuticals Pvt. Ltd
• Johnson & Johnson Services Inc
• Novartis AG
• Ocular Therapeutics, Inc
• Santen Pharmaceuticals Co. Ltd.
• Spectra Vision Care Pvt. Ltd
• Sun Pharmaceuticals Industries Ltd
• Teva Pharmaceutical Industries Ltd

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.